XML 82 R32.htm IDEA: XBRL DOCUMENT v3.19.3
Goodwill and Other Intangibles (Tables)
9 Months Ended
Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of changes in the carrying amount of goodwill
Changes in the carrying amount of our goodwill for the nine months ended September 30, 2019 were as follows (in thousands):
 
Branded Pharmaceuticals
 
Sterile Injectables
 
Generic Pharmaceuticals
 
International Pharmaceuticals
 
Total
Goodwill as of December 31, 2018
$
828,818

 
$
2,731,193

 
$
151,108

 
$
53,517

 
$
3,764,636

Effect of currency translation

 

 

 
1,794

 
1,794

Goodwill impairment charges

 

 
(151,108
)
 

 
(151,108
)
Goodwill as of September 30, 2019
$
828,818

 
$
2,731,193

 
$

 
$
55,311

 
$
3,615,322


The carrying amounts of goodwill at September 30, 2019 and December 31, 2018 are net of the following accumulated impairments (in thousands):
 
Branded Pharmaceuticals
 
Sterile Injectables
 
Generic Pharmaceuticals
 
International Pharmaceuticals
 
Total
Accumulated impairment losses as of December 31, 2018
$
855,810

 
$

 
$
2,991,549

 
$
456,408

 
$
4,303,767

Accumulated impairment losses as of September 30, 2019
$
855,810

 
$

 
$
3,142,657

 
$
470,181

 
$
4,468,648

Schedule of other intangible assets
Changes in the amount of other intangible assets for the nine months ended September 30, 2019 are set forth in the table below (in thousands).
Cost basis:
Balance as of December 31, 2018
 
Acquisitions
 
Impairments
 
Other (1)
 
Effect of Currency Translation
 
Balance as of September 30, 2019
Indefinite-lived intangibles:
 
 
 
 
 
 
 
 
 
 
 
In-process research and development
$
93,900

 
$

 
$

 
$

 
$

 
$
93,900

Total indefinite-lived intangibles
$
93,900

 
$

 
$

 
$

 
$

 
$
93,900

Finite-lived intangibles:
 
 
 
 
 
 
 
 
 
 
 
Licenses (weighted average life of 14 years)
$
457,402

 
$

 
$

 
$

 
$

 
$
457,402

Tradenames
6,409

 

 

 

 

 
6,409

Developed technology (weighted average life of 11 years)
6,182,015

 

 
(104,660
)
 
(2,196
)
 
7,443

 
6,082,602

Total finite-lived intangibles (weighted average life of 11 years)
$
6,645,826

 
$

 
$
(104,660
)
 
$
(2,196
)
 
$
7,443

 
$
6,546,413

Total other intangibles
$
6,739,726

 
$

 
$
(104,660
)
 
$
(2,196
)
 
$
7,443

 
$
6,640,313

 
 
 
 
 
 
 
 
 
 
 
 
Accumulated amortization:
Balance as of December 31, 2018
 
Amortization
 
Impairments
 
Other (1)
 
Effect of Currency Translation
 
Balance as of September 30, 2019
Finite-lived intangibles:
 
 
 
 
 
 
 
 
 
 
 
Licenses
$
(398,182
)
 
$
(9,726
)
 
$

 
$

 
$

 
$
(407,908
)
Tradenames
(6,409
)
 

 

 

 

 
(6,409
)
Developed technology
(2,877,829
)
 
(408,223
)
 

 
2,196

 
(3,923
)
 
(3,287,779
)
Total other intangibles
$
(3,282,420
)
 
$
(417,949
)
 
$

 
$
2,196

 
$
(3,923
)
 
$
(3,702,096
)
Net other intangibles
$
3,457,306

 
 
 
 
 
 
 
 
 
$
2,938,217


__________
(1)
Other adjustments relate to the removal of certain fully amortized intangible assets.
Schedule of future amortization expense Estimated amortization of intangibles for the five fiscal years subsequent to December 31, 2018 is as follows (in thousands):
2019
$
543,795

2020
$
457,248

2021
$
415,637

2022
$
399,886

2023
$
369,619


Schedule of intangible asset impairment charges including goodwill
During the three and nine months ended September 30, 2019 and 2018, the Company incurred the following goodwill and other intangible asset impairment charges (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
2019
 
2018
Goodwill impairment charges
$

 
$

 
$
151,108

 
$
391,000

Other intangible asset impairment charges
$
4,261

 
$
140,609

 
$
104,660

 
$
217,576